


# Małe krople duża różnica

NOWOŚĆ  
TERAZ  
W OPAKOWANIU  
10 ml



Osiem metaanaliz potwierdza skuteczność *Limosilactobacillus reuteri* Protectis® (*L. reuteri* DSM 17938) w redukowaniu objawów kolki niemowlęcej<sup>1-8</sup>

- Skrócony czas płaczu w przypadku kolki niemowlęcej<sup>9-11</sup>
- Zwiększona liczba wypróżnień w przypadku zaparc czynnościowych niemowląt<sup>14, 18</sup>
- Zmniejszona liczba regurgitacji<sup>12-14</sup>
- Bezpieczne dla niemowląt i dzieci<sup>9-15, 18</sup>
- Wygodne podawanie i dawkowanie

## Badania kliniczne z zastosowaniem *L. reuteri* Protectis® według grup wiekowych\*



Zalecane spożycie: 5 kropli raz dziennie =  $1 \times 10^8$  jtk (100 milionów) żywych bakterii *Limosilactobacillus reuteri* Protectis®.  
Referencje: 1. Sung V et al. (2018) *Lactobacillus reuteri* to Treat Infant Colic: A Meta-analysis. *Pediatrics*. 141:e2017181. 2. Gutiérrez-Castellón P et al. (2017) Efficacy of *Lactobacillus reuteri* DSM 17938 for infantile colic: Systematic review with network meta-analysis. *Medicine (Baltimore)*. 96:e9375. 3. Drly R et al. (2018) Probiotics for management of infantile colic: a systematic review of randomized controlled trials. *Arch Med Sci*. 14:1137-1143. 4. Schreck Bird A et al. (2017) Probiotics for the Treatment of Infantile Colic: A Systematic Review. *J Pharm Pract*. 30:366-374. 5. Harb T et al. (2016) Infant Colic—What works? A Systematic Review of Interventions for Breast-fed Infants. *J Pediatr Gastroenterol Nutr*. 62:668-86. 6. Xu M et al. (2015) The Efficacy and Safety of the Probiotic Bacterium *Lactobacillus reuteri* DSM 17938 for Infantile Colic: A Meta-Analysis of Randomized Controlled Trials. *PLoS One*. 10:e014445. 7. Urbanska M et al. (2014) The efficacy of *Lactobacillus reuteri* DSM 17938 for the Management of Infantile Colic in Breastfed Infants: A Randomized, Double-Blind, Placebo-Controlled Trial. *J Pediatr*. 162:257-262. 8. Andbreess J et al. (2013) Probiotics for infantile colic: a systematic review. *BMC Pediatr*. 13:186. 9. Szajewska H et al. (2013) *Lactobacillus reuteri* DSM 17938 in infants with infantile colic: A randomized, double-blind, placebo-controlled trial. *Pediatrics*. 126:e526-e533. 11. Savino F et al. (2007) *Lactobacillus reuteri* ATCC 55730 versus Simethicone in the treatment of infantile colic: a prospective randomized study. *Pediatrics*. 119:124-130. 12. Indrio F et al. (2008) The effects of probiotics on feeding tolerance, bowel habits, and gastro-intestinal motility in preterm newborns. *J Pediatrics*. 152:801-806. 13. Indrio F et al. (2011) *Lactobacillus reuteri* accelerates gastric emptying and improves regurgitation in infants. *Eur J Clin Invest*. 41:417-422. 14. Indrio F et al. (2014) Propylactic Use of a Probiotic in the Prevention of Colic, Regurgitation, and Functional Constipation: A Randomized Clinical Trial. *JAMA Pediatr*. 168(3):228-233. 15. Weizman Z et al. (2005) Effect of a probiotic infant formula on infections in child care centers: Comparison of two probiotic agents. *Pediatrics*. 115:5-9. 16. Abrahamsson TR et al. (2007) Probiotics in prevention of IgE-associated eczema: a double-blind randomized placebo-controlled trial. *J Allergy Clin Immunol*. 119:114-118. 17. Abrahamsson TR et al. (2013) No effect of probiotics on respiratory allergies: a seven-year follow-up of a randomized controlled trial in infancy. *Pediatr Allergy Immunol*. 24: 556-561. 18. Coccuzzello P et al. (2010) *Lactobacillus reuteri* (DSM17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. *J Pediatr*. 157:598-602.

\*Badania nad *L. reuteri* Protectis obejmują badania nad *L. reuteri* DSM17938 i jego szczeppem macierzystym ATCC PTA 55730.  
Dane opracowane przez Scientific Affairs, BioGaia AB, maj 2024r.



**Ewopharma AG Sp. z o.o.**  
01-192 Warszawa | ul. Leszno 14  
info@ewopharma.pl

**BioGaia AB**  
P.O. BOX 3242 SE-103 64 | Sztokholm SZWECA  
www.biogaia.com  
BIO-PL-0010-2025  
Zatwierdzono: LUT-2025

**BioGaia**®